Forget Zepbound: Lilly's Next Stock Signal for Investors
Lilly’s Zepbound has shaken up the obesity-drug market, but the real upside could come from its next-generation candi...
Check which passive funds beat the market in 2024 retirement planning and what factors contributed to their outperformance.
28,482 articlesLilly’s Zepbound has shaken up the obesity-drug market, but the real upside could come from its next-generation candi...
A potential power crunch may unlock a rare upside for energy investors. This guide explains why baseload assets like ...
Prediction markets are rising in prominence ahead of the 2026 midterms, with platforms pricing in geopolitical bets a...
A veteran market strategist argues Big Tech is underappreciated as earnings grow and capital spending remains durable...
Regulators are advancing new crypto rules that could change trading, custody, and enforcement. This guide breaks down...
Biotech investors chase game-changing tech, but CRISPR Therapeutics carries real regulatory milestones and execution ...
Connecticut lawmakers introduced Senate Bill 340 to require public marketing of most 1-4 unit residential listings, w...
BioNTech’s stock is under pressure as investors react to weak guidance and leadership pivots. This deep dive breaks d...
SoundHound AI reports a 59% rise in Q4 revenue and a narrowed EBITDA loss, yet the stock has fallen year-to-date amid...
A fresh set of loan programs is rolling out as mortgage rates stay high and prices stay elevated, aiming to ease the ...
SanDisk has enjoyed a dramatic rally, but traders are wrestling with whether the rally can run further as memory cycl...
When a CEO sells 38,000 Innodata shares, investors often wonder if the move signals trouble or simply a personal liqu...